Payment overview · 2025
General Payments
$934.29
54 reported records · 22 companies
Healthcare provider profile · identity verified
Robin L Matson, MD
Allopathic & Osteopathic Physicians|Family Medicine · KINGFISHER, OK · NPI 1154378644
Verified facts
What the public records show
CMS Open Payments records show Robin L Matson, MD received $934.29 in general payments during 2025 across 54 reported records.
ABBVIE INC. accounted for 14.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Movantik, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Gemtesa by this doctor in 2024.
Valinor Pharma, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOVANTIK as an associated drug or biological on 4139 records involving 1847 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Movantik by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $138.83 | 14.9% | 15 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $122.25 | 13.1% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $66.32 | 7.1% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.63 | 6.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.17 | 5.9% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $51.32 | 5.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.20 | 5.4% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $45.19 | 4.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $39.78 | 4.3% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $38.16 | 4.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $37.10 | 4.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.38 | 3.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.19 | 2.9% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $25.23 | 2.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.53 | 2.5% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.49 | 2.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.86 | 2.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.97 | 1.9% | 1 | 2025 |
| Valinor Pharma, LLC | Unresolved — no canonical attribution shown | $16.95 | 1.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.70 | 1.8% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $16.45 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.59 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $934.29 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $122.25 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $89.98 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $70.61 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $70.61 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $68.22 | 10 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $66.32 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $56.63 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $55.17 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $51.32 | 3 | 2025 |
Source payment records
|
|||||
| VIA MATRIX Normalized: via matrix |
Medical Supply | Organogenesis Inc. | $45.19 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $38.16 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $37.10 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.38 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.38 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.53 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| MOVANTIK Normalized: movantik |
Drug | Valinor Pharma, LLC | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 64 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOVANTIK movantik |
2025 | Movantik | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 87 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
87 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
119 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Valinor Pharma, LLC Exact reporting entity; no affiliate inference |
2025 | MOVANTIK open payments reported associated product |
CMS Open Payments — General Payments 4139 supporting records · 1847 recipient NPIs · example record 1248445875 |
Movantik · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 976 | 125 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 528 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 417 | 122 |
| Gabapentin | Gabapentin | 397 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 347 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 322 | 86 |
| Oxycodone Hcl | Oxycodone Hcl | 263 | 31 |
| Omeprazole | Omeprazole | 254 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 52 |
| Lisinopril | Lisinopril | 211 | 53 |
| Pregabalin | Pregabalin | 201 | 34 |
| Losartan Potassium | Losartan Potassium | 175 | 46 |
| Mounjaro | Tirzepatide | 175 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 164 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 43 |
| Celecoxib | Celecoxib | 157 | 43 |
| Trazodone Hcl | Trazodone Hcl | 156 | 33 |
| Potassium Chloride | Potassium Chloride | 152 | 36 |
| Jardiance | Empagliflozin | 146 | 25 |
| Metformin Hcl | Metformin Hcl | 144 | 36 |
| Fenofibrate | Fenofibrate,micronized | 139 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 22 |
| Furosemide | Furosemide | 134 | 42 |
| Fenofibrate | Fenofibrate Nanocrystallized | 133 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 131 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 32 |
| Eliquis | Apixaban | 119 | 26 |
| Fenofibrate | Fenofibrate | 119 | 40 |
| Sertraline Hcl | Sertraline Hcl | 115 | 31 |
| Meloxicam | Meloxicam | 110 | 29 |
| Ondansetron Odt | Ondansetron | 110 | 32 |
| Tramadol Hcl | Tramadol Hcl | 106 | 23 |
| Buprenorphine Hcl | Buprenorphine Hcl | 99 | 13 |
| Clonidine Hcl | Clonidine Hcl | 98 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 28 |
| Morphine Sulfate Er | Morphine Sulfate | 79 | suppressed |
| Finasteride | Finasteride | 76 | 17 |
| Simvastatin | Simvastatin | 76 | 18 |
| Ibuprofen | Ibuprofen | 74 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 14 |
| Lovastatin | Lovastatin | 66 | 12 |
| Xarelto | Rivaroxaban | 66 | suppressed |
| Aripiprazole | Aripiprazole | 65 | 21 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 65 | 18 |
| Farxiga | Dapagliflozin Propanediol | 64 | 11 |
| Methylprednisolone | Methylprednisolone | 63 | 50 |
| Azithromycin | Azithromycin | 62 | 49 |
| Carvedilol | Carvedilol | 61 | 17 |
| Allopurinol | Allopurinol | 60 | 16 |
| Buspirone Hcl | Buspirone Hcl | 59 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 42 |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Alprazolam | Alprazolam | 56 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 13 |
| Ezetimibe | Ezetimibe | 45 | 12 |
| Montelukast Sodium | Montelukast Sodium | 45 | 15 |
| Prednisone | Prednisone | 45 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 44 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 23 |
| Belsomra | Suvorexant | 41 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 41 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Olanzapine | Olanzapine | 39 | suppressed |
| Sucralfate | Sucralfate | 39 | 13 |
| Fentanyl | Fentanyl | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 12 |
| Nifedipine Er | Nifedipine | 37 | 11 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Lansoprazole | Lansoprazole | 29 | 11 |
| Meclizine Hcl | Meclizine Hcl | 29 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Glyburide | Glyburide | 26 | suppressed |
| Oxycontin | Oxycodone Hcl | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 18 |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Movantik | Naloxegol Oxalate | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $934.29 · 54 records | ABBVIE INC. | AIRSUPRA, AUSTEDO XR, Auvelity, FANAPT, FARXIGA, GEMTESA, GVOKE HYPOPEN, Kerendia, LOREEV XR, MOVANTIK, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, Qelbree, REPATHA, REXULTI, Senza, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VIA MATRIX, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error